EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) [2]
| dc.authorid | 0000-0002-4607-5660 | |
| dc.contributor.author | Powles, T. B. | |
| dc.contributor.author | Valderrama, B. Perez | |
| dc.contributor.author | Gupta, S. | |
| dc.contributor.author | Bedke, J. | |
| dc.contributor.author | Kikuchi, E. | |
| dc.contributor.author | Hoffman-Censits, J. | |
| dc.contributor.author | Iyer, G. | |
| dc.date.accessioned | 2025-05-10T19:48:33Z | |
| dc.date.issued | 2023 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description | Congress of the European-Society-for-Medical-Oncology (ESMO) -- OCT 20-24, 2023 -- Madrid, SPAIN | |
| dc.description.abstract | [No abstract available] | |
| dc.description.sponsorship | European Soc Med Oncol | |
| dc.description.sponsorship | Seagen Inc., Bothell, WA, USA; Astellas Pharma, Northbrook, IL, USA; Merck Sharp Dohme LLC | |
| dc.description.sponsorship | Funded by Seagen Inc., Bothell, WA, USA; Astellas Pharma, Northbrook, IL, USA; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. | |
| dc.identifier.doi | 10.1016/j.annonc.2023.10.106 | |
| dc.identifier.endpage | S1340 | |
| dc.identifier.issn | 0923-7534 | |
| dc.identifier.issn | 1569-8041 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.startpage | S1340 | |
| dc.identifier.uri | https://doi.org/10.1016/j.annonc.2023.10.106 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/11748 | |
| dc.identifier.volume | 34 | |
| dc.identifier.wos | WOS:001087480203591 | |
| dc.identifier.wosquality | Q1 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Annals of Oncology | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.title | EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) [2] | |
| dc.type | Conference Object |
Dosyalar
Orijinal paket
1 - 1 / 1










